InvestorsHub Logo
Followers 72
Posts 6896
Boards Moderated 0
Alias Born 12/07/2011

Re: Yooper61 post# 215288

Thursday, 02/01/2018 9:05:06 AM

Thursday, February 01, 2018 9:05:06 AM

Post# of 403039
I think he was talking about B-OM ONLY. The most recent deal only included 1 million upfront for a B-OM drug in Sept. it carried a 100+ million milestone and increasing double digit royalty though. B-OM is much better though, so I expect more, like Bio said, maybe 10-15 million upfront with trials covered and a bigger milestone especially if BTD is granted.

If you are thinking it’s going to be a mega B deal....than the upfront imo would be in the hundred millions and huge-milestones for each indication, and regulatory approval.

A full B deal for the franchise would equate to billions imo by the time they reached regulatory submission.

IBD, B-OM, Dermatology, Antibiotic

That would garner Humira style revenue easily. EASILY. And I’m talking end game - crohns, acne, etc... when the dust settles in 5 years I think all of B could bring in Humira type revs.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News